Table 2.
Patient outcomes according to admission NT‐proBNP
| Characteristic | Low a NT‐proBNP (N = 417) | P value | Borderline NT‐proBNP (N = 141) | P value | High NT‐proBNP (N = 121) | P value |
|---|---|---|---|---|---|---|
| Mortality | ||||||
| Events at 28 days, N (%) | 24 (5.8) | 29 (20.6) | 44 (36.4) | |||
| Unadjusted HR (95%CI) | 1.00 | Ref. | 3.87 (2.26–6.62) | <0.001 | 7.86 (4.78–12.9) | <0.001 |
| Adjusted HR (95%CI) b | 1.00 | Ref. | 1.44 (0.70–2.97) | 0.322 | 2.15 (1.06–4.39) | 0.034 |
| Composite | ||||||
| Events at 28 days, N (%) | 99 (23.7) | 50 (35.5) | 58 (47.9) | |||
| Unadjusted HR (95%CI) | 1.00 | Ref. | 1.61 (1.15–2.25) | 0.006 | 2.47 (1.78–3.43) | <0.001 |
| Adjusted HR (95%CI) b | 1.00 | Ref. | 1.34 (0.87–2.07) | 0.186 | 1.66 (1.04–2.66) | 0.035 |
a
Categories of NT‐proBNP defined as in Table 1 .
b
Adjusted for age, sex, race, history of hypertension, coronary artery disease, and chronic kidney disease, days from symptom onset, systolic blood pressure, temperature, creatinine, d‐dimer, troponin T, alanine aminotransferase, procalcitonin, and QTc on presentation.
CI, confidence interval; HR, hazard ratio; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.